Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced
today that it plans to report first quarter 2009 financial results on
May 6, 2009, following the close of market. Ligand’s President and CEO,
John L. Higgins, Vice President of Finance and CFO, John Sharp will host
the conference call.
|
|
|
|
|
|
|
|
|
What:
|
|
|
|
|
|
Ligand Pharmaceuticals conference call to discuss financial results
and
|
|
|
|
|
|
|
|
provide general business updates.
|
|
|
|
When:
|
|
|
|
|
|
May 6, 2009
|
|
|
|
Time:
|
|
|
|
|
|
1:30 p.m. Pacific time (4:30 p.m. Eastern time)
|
|
|
|
Webcast:
|
|
|
|
|
|
Conference call and replay accessible at www.ligand.com.
|
|
|
|
Conference Call:
|
|
|
|
|
|
(877) 356-5578, ID # 95536060 (U.S.)
|
|
|
|
Replay:
|
|
|
|
|
|
(800) 642-1687, ID # 95536060 (U.S.)
|
|
|
|
|
|
|
|
Replay of conference call will be available from
|
|
|
|
|
|
|
|
May 7, 2009 to June 8, 2009.
|
|
|
|
|
|
|
|
|
About Ligand Pharmaceuticals
Ligand discovers and develops new drugs that address critical unmet
medical needs of patients with muscle wasting, frailty, hormone-related
diseases, osteoporosis, inflammatory diseases, anemia, asthma,
rheumatoid arthritis and psoriasis. Ligand's proprietary drug discovery
and development programs are based on advanced cell-based assays,
gene-expression tools, ultra-high throughput screening and one of the
world’s largest combinatorial chemical libraries. Ligand has strategic
alliances with major pharmaceutical and biotechnology companies,
including Bristol-Myers Squibb, Celgene, Cephalon, GlaxoSmithKline,
Schering-Plough, Pfizer and Wyeth Pharmaceuticals. With nine
pharmaceutical deals and more than twenty different molecules in various
stages of development, Ligand utilizes proprietary technologies for
identifying drugs with novel receptor and enzyme drug targets.
Ligand Pharmaceuticals Incorporated
John L. Higgins, President and
CEO or
Erika Luib, Investor Relations
(858) 550-7896
or
Lippert/Heilshorn
& Associates
Don Markley
(310) 691-7100
dmarkley@lhai.com
